Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study
Recruiting in Palo Alto (17 mi)
Overseen ByNikhil Khushalani, MD
Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase < 1
Waitlist Available
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
No Placebo Group
Approved in 3 jurisdictions
Trial Summary
What is the purpose of this trial?This study will treat resectable cutaneous squamous cell carcinoma patients with pramlintide for two weeks prior to surgical resection of their tumor. Pre-treatment and surgical resection specimens will then be analyzed for biological alterations.
Eligibility Criteria
Participant Groups
3Treatment groups
Experimental Treatment
Group I: Cohort 3: Pramlintide 120 mcg three times dailyExperimental Treatment1 Intervention
Participants will self inject Parmlintide 120 mcg three times daily for two weeks prior to surgical resection of tumor.
Group II: Cohort 2: Pramlintide 60 mcg three times dailyExperimental Treatment1 Intervention
Participants will self inject Parmlintide 60 mcg three times daily for two weeks prior to surgical resection of tumor.
Group III: Cohort 1: Pramlintide 60 mcg twice dailyExperimental Treatment1 Intervention
Participants will self inject Pramlintide 60 mcg twice daily for two weeks prior to surgical resection of tumor.
Pramlintide is already approved in United States, European Union, Canada for the following indications:
🇺🇸 Approved in United States as Symlin for:
- Type 1 diabetes
- Type 2 diabetes
🇪🇺 Approved in European Union as Symlin for:
- Type 1 diabetes
- Type 2 diabetes
🇨🇦 Approved in Canada as Symlin for:
- Type 1 diabetes
- Type 2 diabetes
Find A Clinic Near You
Research locations nearbySelect from list below to view details:
Moffitt Cancer CenterTampa, FL
Loading ...
Who is running the clinical trial?
H. Lee Moffitt Cancer Center and Research InstituteLead Sponsor